BRPI0407651A - compostos, métodos para a preparação de um composto, composição e farmacêutica, método para ligação ao receptor de urotensina ii, método para ligação ao receptor de somatostatina 5, método para o tratamento de doenças e distúrbios, método de alteração da pressão vascular em um mamìfero, método de alteração da velocidade cardìaca em um mamìfero e método de alteração da atividade locomotora de um mamìfero - Google Patents
compostos, métodos para a preparação de um composto, composição e farmacêutica, método para ligação ao receptor de urotensina ii, método para ligação ao receptor de somatostatina 5, método para o tratamento de doenças e distúrbios, método de alteração da pressão vascular em um mamìfero, método de alteração da velocidade cardìaca em um mamìfero e método de alteração da atividade locomotora de um mamìferoInfo
- Publication number
- BRPI0407651A BRPI0407651A BRPI0407651-6A BRPI0407651A BRPI0407651A BR PI0407651 A BRPI0407651 A BR PI0407651A BR PI0407651 A BRPI0407651 A BR PI0407651A BR PI0407651 A BRPI0407651 A BR PI0407651A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- altering
- receptor binding
- urotensin
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 13
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 102000005962 receptors Human genes 0.000 title abstract 4
- 108020003175 receptors Proteins 0.000 title abstract 4
- 102000005157 Somatostatin Human genes 0.000 title abstract 2
- 108010056088 Somatostatin Proteins 0.000 title abstract 2
- 102000012327 Urotensin II receptors Human genes 0.000 title abstract 2
- 108050002984 Urotensin II receptors Proteins 0.000 title abstract 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 2
- 229960000553 somatostatin Drugs 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 3
- 230000000747 cardiac effect Effects 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 230000006742 locomotor activity Effects 0.000 title 1
- 230000002792 vascular Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- HFNHAPQMXICKCF-USJMABIRSA-N urotensin-ii Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O HFNHAPQMXICKCF-USJMABIRSA-N 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108050001286 Somatostatin Receptor Proteins 0.000 abstract 1
- 102000011096 Somatostatin receptor Human genes 0.000 abstract 1
- 102000050488 Urotensin II Human genes 0.000 abstract 1
- 108010018369 Urotensin II Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003137 locomotive effect Effects 0.000 abstract 1
- 238000013507 mapping Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C225/18—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings the carbon skeleton containing also rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
COMPOSTOS, MéTODOS PARA A PREPARAçãO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA LIGAçãO AO RECEPTOR DE UROTENSINA II, MéTODO PARA LIGAçãO AO RECEPTOR DE SOMATOSTATINA 5, MéTODO PARA O TRATAMENTO DE DOENçAS E DISTúRBIOS, MéTODO DE ALTERAçãO DA PRESSãO VASCULAR EM UM MAMìFERO, MéTODO DE ALTERAçãO DA VELOCIDADE CARDìACA EM UM MAMìFERO E MéTODO DE ALTERAçãO DA ATIVIDADE LOCOMOTORA DE UM MAMìFERO. A presente invenção apresenta uma abordagem combinatória para uma biblioteca de novos compostos que têm quatro pontos de diversidade. Os compostos propiciam o mapeamento dos receptores de urotensina II e de somatostatina 5 pela ligação diferencial dos ditos receptores. A presente invenção também se refere a um método de tratamento de doenças para as quais a modulação do receptor de urotensina II produz uma resposta fisiologicamente benéfica na dita doença, tais como aquelas associadas com a função do CNS e as doenças cardiovasculares. A presente invenção também se refere ainda a composições farmacêuticas que compreendem esses agentes para o tratamento dessas doenças adaptadas para modular o receptor de urotensina II.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44862903P | 2003-02-19 | 2003-02-19 | |
| PCT/US2004/004765 WO2004073642A2 (en) | 2003-02-19 | 2004-02-18 | 2-aminoethyl substituted pyrimidin-2-ones, cyclopropanes, pyrazolines, pyrimidines and benzothiazepines and their use as urotensin ii and somatostatin 5 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0407651A true BRPI0407651A (pt) | 2006-02-21 |
Family
ID=32908620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0407651-6A BRPI0407651A (pt) | 2003-02-19 | 2004-02-18 | compostos, métodos para a preparação de um composto, composição e farmacêutica, método para ligação ao receptor de urotensina ii, método para ligação ao receptor de somatostatina 5, método para o tratamento de doenças e distúrbios, método de alteração da pressão vascular em um mamìfero, método de alteração da velocidade cardìaca em um mamìfero e método de alteração da atividade locomotora de um mamìfero |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100029612A1 (pt) |
| EP (1) | EP1638946A2 (pt) |
| JP (1) | JP2006520328A (pt) |
| KR (1) | KR20050100695A (pt) |
| CN (1) | CN1751029A (pt) |
| AU (1) | AU2004213000A1 (pt) |
| BR (1) | BRPI0407651A (pt) |
| CA (1) | CA2515706A1 (pt) |
| MX (1) | MXPA05008802A (pt) |
| RU (1) | RU2005129099A (pt) |
| WO (1) | WO2004073642A2 (pt) |
| ZA (1) | ZA200506625B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2970651B1 (fr) * | 2011-01-25 | 2013-03-01 | Ct Hospitalier Universitaire Rouen | Urotensine ii et agonistes du recepteur de l'urotensine ii pour utilisation dans le traitement symptomatique du choc septique |
| JP6379805B2 (ja) * | 2013-09-17 | 2018-08-29 | 株式会社リコー | 情報処理プログラム、情報処理装置および情報処理システム |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2683742A (en) * | 1951-02-23 | 1954-07-13 | Searle & Co | Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives |
| US2793212A (en) * | 1953-12-09 | 1957-05-21 | Lilly Co Eli | Substituted benzamidopiperidinopropanes |
| US3096329A (en) * | 1957-10-15 | 1963-07-02 | Sterling Drug Inc | Triazolo [b] pyridazines |
| GB1143703A (pt) * | 1965-03-18 | |||
| US3401166A (en) * | 1966-08-01 | 1968-09-10 | Squibb & Sons Inc | Therapeutically active benzothiazines |
| US3880885A (en) * | 1971-11-23 | 1975-04-29 | Sandoz Ag | Tertiary aminoethyl isochromans and isocoumarins |
| DE3243518A1 (de) * | 1982-11-25 | 1984-05-30 | Basf Ag, 6700 Ludwigshafen | Substituierte 1-oxo-2-phenyl-2-(2-alkylaminoethyl)-1,2,3,4- tetrahydronaphthaline, ihre herstellung und verwendung |
| US5707798A (en) * | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
| US6605623B1 (en) * | 1998-12-18 | 2003-08-12 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6511994B2 (en) * | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
-
2004
- 2004-02-18 JP JP2006503667A patent/JP2006520328A/ja not_active Withdrawn
- 2004-02-18 WO PCT/US2004/004765 patent/WO2004073642A2/en active Application Filing
- 2004-02-18 BR BRPI0407651-6A patent/BRPI0407651A/pt not_active IP Right Cessation
- 2004-02-18 CA CA002515706A patent/CA2515706A1/en not_active Abandoned
- 2004-02-18 RU RU2005129099/04A patent/RU2005129099A/ru not_active Application Discontinuation
- 2004-02-18 KR KR1020057015324A patent/KR20050100695A/ko not_active Application Discontinuation
- 2004-02-18 AU AU2004213000A patent/AU2004213000A1/en not_active Abandoned
- 2004-02-18 US US10/568,149 patent/US20100029612A1/en not_active Abandoned
- 2004-02-18 MX MXPA05008802A patent/MXPA05008802A/es not_active Application Discontinuation
- 2004-02-18 CN CNA2004800046476A patent/CN1751029A/zh active Pending
- 2004-02-18 EP EP04712329A patent/EP1638946A2/en not_active Withdrawn
-
2005
- 2005-08-18 ZA ZA200506625A patent/ZA200506625B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004213000A1 (en) | 2004-09-02 |
| CA2515706A1 (en) | 2004-09-02 |
| RU2005129099A (ru) | 2006-04-20 |
| KR20050100695A (ko) | 2005-10-19 |
| MXPA05008802A (es) | 2005-10-18 |
| ZA200506625B (en) | 2006-08-30 |
| JP2006520328A (ja) | 2006-09-07 |
| CN1751029A (zh) | 2006-03-22 |
| US20100029612A1 (en) | 2010-02-04 |
| WO2004073642A3 (en) | 2005-03-17 |
| WO2004073642A2 (en) | 2004-09-02 |
| EP1638946A2 (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0214553A (pt) | Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas | |
| BR9911358A (pt) | Derivados de 1,3-oxazolina e 1,3-tiazolina, processos para a sua preparação e sua aplicação como composições praguicidas | |
| BRPI0413490A (pt) | novos compostos | |
| BR9909991A (pt) | Derivados de 1{(-4-piperidinil-1-substituìdos)metil]-4-piperidina, processo para a sua produção, composições medicinais contendo-os, e intermediários destes compostos | |
| DE60116112D1 (de) | Ernährungszusammensetzung | |
| BRPI0517846A (pt) | azaindolcarboxamidas | |
| WO1999063930A3 (en) | Novel angiotensin receptor modulators and their uses | |
| BR0314635A (pt) | Derivados de piridina como moduladores de receptores de cb2 | |
| BR9811902A (pt) | Compostos de confeito pesado com sabor modificado contendo ingredientes funcionais | |
| BRPI0512352A (pt) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
| WO2006108582A3 (en) | Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis | |
| BRPI0410746A (pt) | compostos e composições imunossupressoras | |
| BR0010555A (pt) | Inibidores de neuraminidases | |
| BR9706448A (pt) | Produtos cereal gelatinizado contendo oligossacarìdeo | |
| DZ3402A1 (fr) | Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement | |
| BR0309106A (pt) | Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm | |
| MY160357A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| CY1112139T1 (el) | Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης | |
| BR0317222A (pt) | Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas | |
| AU7566601A (en) | Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases | |
| HK1105197A1 (en) | Pyrimido-benzimidazole derivatives and the use thereof in the form of agonists or antagonists of melanocortin receptors | |
| BR0214140A (pt) | Derivados de piperidina e sua utilização como moduladores da atividade de receptor de quimiocina (especialmente ccr5) | |
| MXPA05010384A (es) | Composiciones adherentes para el cuidado de la piel y articulos que tienen las composiciones adherentes para el cuidado de la piel colocadas encima. | |
| BR0207881A (pt) | Método para a identificação de compostos para regular a massa ou a função muscular usando receptores do fator de liberação de corticotropina | |
| BRPI0417167A (pt) | composições para animais de estimação compreendendo oligofrutose de cadeia curta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |